Dermapharm Holding SE (DMP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dermapharm Holding SE (DMP) has a cash flow conversion efficiency ratio of 0.330x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€229.17 Million ≈ $267.92 Million USD) by net assets (€694.38 Million ≈ $811.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Dermapharm Holding SE - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Dermapharm Holding SE's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read DMP total liabilities for a breakdown of total debt and financial obligations.
Dermapharm Holding SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dermapharm Holding SE ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiaozuo Wanfang Aluminum
SHE:000612
|
0.020x |
|
Sichuan Swellfun Co Ltd
SHG:600779
|
-0.072x |
|
Knowles Cor
NYSE:KN
|
0.061x |
|
Central Puerto S.A.
BA:CEPU
|
0.074x |
|
Inv La Constru
SN:ILC
|
0.106x |
|
Piramal Pharma Limited
NSE:PPLPHARMA
|
0.046x |
|
Santam
JSE:SNT
|
-0.032x |
|
Bayer Cropscience Limited
NSE:BAYERCROP
|
-0.011x |
Annual Cash Flow Conversion Efficiency for Dermapharm Holding SE (2014–2025)
The table below shows the annual cash flow conversion efficiency of Dermapharm Holding SE from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Dermapharm Holding SE stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €694.38 Million ≈ $811.80 Million |
€229.17 Million ≈ $267.92 Million |
0.330x | -0.31% |
| 2024-12-31 | €608.29 Million ≈ $711.16 Million |
€201.38 Million ≈ $235.43 Million |
0.331x | -17.77% |
| 2023-12-31 | €545.05 Million ≈ $637.22 Million |
€219.42 Million ≈ $256.53 Million |
0.403x | -25.70% |
| 2022-12-31 | €532.49 Million ≈ $622.54 Million |
€288.53 Million ≈ $337.33 Million |
0.542x | +8.18% |
| 2021-12-31 | €499.83 Million ≈ $584.36 Million |
€250.37 Million ≈ $292.71 Million |
0.501x | +24.02% |
| 2020-12-31 | €324.58 Million ≈ $379.47 Million |
€131.10 Million ≈ $153.27 Million |
0.404x | +14.20% |
| 2019-12-31 | €284.49 Million ≈ $332.60 Million |
€100.61 Million ≈ $117.63 Million |
0.354x | -43.08% |
| 2018-12-31 | €256.08 Million ≈ $299.39 Million |
€159.13 Million ≈ $186.04 Million |
0.621x | -47.21% |
| 2017-12-31 | €73.69 Million ≈ $86.15 Million |
€86.74 Million ≈ $101.40 Million |
1.177x | -6.78% |
| 2016-12-31 | €60.81 Million ≈ $71.09 Million |
€76.78 Million ≈ $89.76 Million |
1.263x | +38.98% |
| 2015-12-31 | €44.44 Million ≈ $51.96 Million |
€40.38 Million ≈ $47.20 Million |
0.909x | -43.05% |
| 2014-12-31 | €34.01 Million ≈ $39.76 Million |
€54.26 Million ≈ $63.43 Million |
1.595x | -- |
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, a… Read more